Get started
Intellia Therapeutics, Inc.
Long

NTLA - Inverse head & shoulders

By dvdgege5
Updated
An inverse head & shoulders pattern formed in the charts of Intellia, a company developing CRISPR gene-editing therapy. While CRISPR has not been approved to begin human trials in the US, it has already been tested on over 80 patients in China.

Target: $31 (previous closing high), or long term hold
Stop: $18 - $20
Note
Note: 2 other companies also developing CRISPR-Cas9 tech are CRSP and EDIT. Their stocks have skyrocketed the past month. It is advisable to wait for a correction before taking a position on them.
Trade closed: target reached
It wasn't a straightforward journey, but got there on time anyway! I hope everyone reading took profits at $31 (or even higher)
BIObiotechcrisprHEADHead and ShoulderspatternshouldersTECHTrend Analysis
dvdgege5

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.